VYVGART™ (efgartigimod alfa-fcab) is currently FDA approved for the treatment of adults with generalized myasthenia gravis who are anti-AChR antibody positive. This presentation the MGFA's Resarch Webinar Series shares how the treatment works. Recorded February 2022.
Негізгі бет Research Webinar: Learn about VYVGART™ for generalized myasthenia gravis
No video
Пікірлер: 9